Novel ruthenium complexes and compositions for cancer therapy

Novel ruthenium polypyridyl complexes address the limitations of existing anticancer drugs by effectively treating triple-negative breast cancer and EGFR gene mutation-positive lung cancer, demonstrating high therapeutic potential.

JP2024169843APending Publication Date: 2024-12-06KANSAI UNIVERSITY +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023086639
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-26
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing anticancer drugs like cisplatin and carboplatin induce resistant cancers and lack efficacy against specific types such as triple-negative breast cancer and EGFR gene mutation-positive lung cancer.

Method used

Development of novel ruthenium polypyridyl complexes, specifically [Ru(47dpphen)2(5dmbpy)](PF6)2 and [Ru(47dpphen)2(4dmbpy)](PF6), which are used as active ingredients in cancer treatment compositions targeting breast, lung, and other cancers.

Benefits of technology

The ruthenium complexes exhibit excellent anticancer effects, particularly against triple-negative breast cancer and EGFR gene mutation-positive lung cancer, offering a potential solution to drug-resistant cancers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024169843000001_ABST
    Figure 2024169843000001_ABST
Patent Text Reader

Abstract

To provide novel ruthenium complexes and compositions for cancer therapy.SOLUTION: A ruthenium complex ([Ru(47dpphen)2(5dmbpy)]2+), containing 4,7-diphenyl-1,10-phenanthroline and 5,5'-dimethyl-2,2'-bipyridine as ligands, or a pharmaceutically acceptable salt thereof, exhibits superior anticancer activity, particularly against breast cancer, lung cancer, colorectal cancer, cervical cancer, neuroblastoma, and leukemia. Additionally, [Ru(47dpphen)2(4dmbpy)]2+, containing 4,4'-dimethyl-2,2'-bipyridine as ligands, or a pharmaceutically acceptable salt thereof, exhibits superior anticancer activity, particularly against breast cancer, lung cancer, and leukemia.SELECTED DRAWING: Figure 7
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to novel ruthenium complexes and the treatment of cancer. [Background technology]

[0002] Known anticancer drugs include drugs that target DNA, drugs that inhibit cell division by acting on enzymes that promote cell division, drugs that induce apoptosis, etc. Cisplatin and carboplatin are known as anticancer drugs that contain metal complexes as active ingredients, but they are known to induce resistant cancers.

[0003] The antitumor activity of ruthenium polypyridyl complexes has attracted attention in recent years and has been actively studied (Non-Patent Documents 1-4). [Prior art documents] [Non-patent literature]

[0004] [Non-Patent Document 1] Karges J. et al. J. Am. Chem. Soc. 2020, 142, 6578-6587 [Non-Patent Document 2] Fayad C. et al. J. Biol. Inorg. Chem. 2021, 26, 43-55 [Non-Patent Document 3] Gurgul I. et al. J. Med. Chem. 2022, 65, 10459-10470 [Non-Patent Document 4] Colina-Vegas L. et al. J. Inorg. Biochem. 2015, 153, 150-161 Summary of the Invention [Problem to be solved by the invention]

[0005] An object of the present invention is to provide a novel ruthenium complex and a composition for treating cancer. [Means for solving the problem]

[0006] In order to solve the above problems, the present inventors have synthesized many ruthenium polypyridyl complexes having various bipyridines and phenanthrolines as ligands and conducted intensive research, and as a result, have found ruthenium complexes represented by formula (I) and formula (II) having excellent anticancer activity. The present invention includes the following aspects.

[0007] 1. Formula (I): [ka] or a pharmacy acceptable salt thereof. 2. A composition for treating cancer, comprising the ruthenium complex or a pharma- ceutical acceptable salt thereof according to the preceding item 1. 3. The composition according to item 2 above, wherein the cancer is at least one selected from the group consisting of breast cancer, lung cancer, colon cancer, cervical cancer, neuroblastoma, and leukemia. 4. The composition described in item 3 above, wherein the cancer is breast cancer. 5. The composition described in the preceding item 4, wherein the breast cancer is hormone receptor-negative breast cancer. 6. The composition described in the preceding item 5, wherein the hormone receptor-negative breast cancer is triple-negative breast cancer. 7. The composition described in the preceding item 5, wherein the hormone receptor-negative breast cancer is HER2-positive breast cancer. 8. The composition described in the preceding item 3, wherein the cancer is lung cancer. 9. The composition described in the preceding item 8, wherein the lung cancer is EGFR gene mutation-positive lung cancer. 10. The composition described in the preceding item 3, wherein the cancer is neuroblastoma. 11.Formula (II): [ka] or a pharma- ceutical acceptable salt thereof, wherein the cancer is at least one selected from the group consisting of breast cancer, lung cancer, and leukemia. 12. The composition described in the preceding item 11, wherein the cancer is breast cancer. 13. The composition described in the preceding item 12, wherein the breast cancer is hormone receptor-negative breast cancer. 14. The composition described in the preceding item 13, wherein the hormone receptor-negative breast cancer is triple-negative breast cancer. 15. The composition described in the preceding item 13, wherein the hormone receptor-negative breast cancer is HER2-positive breast cancer. 16. The composition described in the preceding item 11, wherein the cancer is lung cancer. 17. The composition described in the preceding item 16, wherein the lung cancer is EGFR gene mutation-positive lung cancer. 18. A method for treating cancer, comprising administering a ruthenium complex represented by the above formula (I) or a pharma- ceutically acceptable salt thereof to a subject in need thereof. 19. A method for treating cancer, comprising administering a ruthenium complex represented by the formula (II) or a pharma- ceutically acceptable salt thereof to a subject in need thereof, wherein the cancer is at least one selected from the group consisting of breast cancer, lung cancer, and leukemia. 20. Use of a ruthenium complex represented by the above formula (I) or a pharma- ceutically acceptable salt thereof for the preparation of a composition for treating cancer. 21. Use of the ruthenium complex represented by the formula (II) or a pharma- ceutical acceptable salt thereof for the preparation of a composition for treating cancer, wherein the cancer is at least one selected from the group consisting of breast cancer, lung cancer, and leukemia. Effect of the Invention

[0008] The ruthenium complexes represented by formula (I) and formula (II) or pharma- ceutically acceptable salts thereof have anti-cancer effects and can be used in the treatment of cancer. The ruthenium complexes represented by formula (I) or pharma- ceutically acceptable salts thereof have excellent anti-cancer effects, particularly against breast cancer, lung cancer, colon cancer, cervical cancer, neuroblastoma, and leukemia. The ruthenium complexes represented by formula (II) or pharma- ceutically acceptable salts thereof have excellent anti-cancer effects against breast cancer, lung cancer, and leukemia. The ruthenium complexes represented by formula (I) and formula (II) or pharma- ceutically acceptable salts thereof exhibit excellent anti-cancer effects against triple-negative breast cancer, which is difficult to treat, and may contribute to future breast cancer treatment. In addition, the ruthenium complexes represented by formula (I) and formula (II) or pharma- ceutically acceptable salts thereof exhibit excellent anti-tumor effects against non-small cell lung carcinoma (NSCLC) patients with EGFR gene mutations, and may contribute to future lung cancer treatment. [Brief description of the drawings]

[0009] [Figure 1] FIG. 1 shows the 1H-NMR spectrum (400 MHz, DMSO-d6, 298 K) of the intermediate [Ru(47dpphen)2Cl2] of Example 1. [Diagram 2] FIG. 2 shows the 1H-NMR spectrum (400 MHz, DMSO-d6, 298 K) of [Ru(47dpphen)2(5dmbpy)](PF6)2 (hereinafter, also referred to as HRM-19) obtained in Example 1. [Diagram 3] FIG. 3 shows the ESI-MS spectrum (solvent: CHCN) of [Ru(47dpphen)2(5dmbpy)](PF6)2(HRM-19) obtained in Example 1. A: measured value, upper B: measured value, lower B: theoretical value [Figure 4] FIG. 4 shows the H-NMR spectrum (400 MHz, DMSO-d, 298 K) of [Ru(47dpphen)(4dmbpy)](PF) (hereinafter, also referred to as HRM-18) obtained in Example 2. [Diagram 5]FIG. 5 shows the ESI-MS spectrum (solvent: CHCN) of [Ru(47dpphen)2(4dmbpy)](PF6)2(HRM-18) obtained in Example 2. A: measured value, upper B: measured value, lower B: theoretical value [Figure 6] FIG. 6 shows the ESI-MS spectrum (solvent: CH3CN) of [Ru(47dpphen)2(bpy)](PF6)2 (hereinafter also referred to as HRM-17) obtained in the comparative example. A: measured value, upper B: measured value, lower B: theoretical value [Figure 7] FIG. 7 is a graph showing the cell viability of human cancer cell lines after addition of a ruthenium complex of the present invention. [Figure 8] FIG. 8 shows the results of cell cycle analysis of the triple-negative breast cancer cell line MDA-MB-231 after addition of a ruthenium complex of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] The ruthenium complex represented by formula (I) is a ruthenium complex having 4,7-diphenyl-1,10-phenanthroline (47dpphen) and 5,5'-dimethyl-2,2'-bipyridine (5dmbpy) as ligands. In this specification, the ruthenium complex represented by formula (I) is referred to as [Ru(47dpphen)2(5dmbpy)]. 2+ The composition for cancer treatment of the present invention contains a ruthenium complex represented by formula (I) or a pharma- ceutically acceptable salt thereof as an active ingredient.

[0011] The cancer treatment composition of the present invention contains a ruthenium complex represented by formula (II) or a pharma- ceutically acceptable salt thereof as an active ingredient. The ruthenium complex represented by formula (II) is a ruthenium complex having 4,7-diphenyl-1,10-phenanthroline (47dpphen) and 4,4'-dimethyl-2,2'-bipyridine (4dmbpy) as ligands. In this specification, the ruthenium complex represented by formula (II) is referred to as [Ru(47dpphen)2(4dmbpy)]. 2+ It can also be expressed as.

[0012] In this specification, the ruthenium complex of the present invention means a ruthenium complex represented by formula (I) or formula (II) or a pharma- ceutically acceptable salt thereof.

[0013] The ruthenium complex in the present invention may be in a free form (dication form) or in a salt form.

[0014] Examples of the pharma- ceutically acceptable salts include hexafluorophosphate, chloride, bromide, iodide, sulfate, nitrate, phosphate, formate, acetate, propionate, fumarate, oxalate, malonate, succinate, methanesulfonate, ethanesulfonate, benzenesulfonate, toluenesulfonate, maleate, dimaleate, lactate, malate, tartrate, citrate, pamoate, trifluoroacetate, perchlorate, tetrafluoroborate, tetraphenylborate, etc. Preferred salts include hexafluorophosphate, chloride, perchlorate, and tetrafluoroborate.

[0015] In this specification, the hexafluorophosphate salt of the ruthenium complex represented by formula (I) ([Ru(47dpphen)2(5dmbpy)](PF6)2) is also referred to as HRM-19. In addition, in this specification, the hexafluorophosphate salt of the ruthenium complex represented by formula (II) ([Ru(47dpphen)2(4dmbpy)](PF6)2) is also referred to as HRM-18.

[0016] The ruthenium complexes in the present invention include any of their solvates, hydrates, cocrystals, and the like.

[0017] The ruthenium complex in the present invention can exist as a plurality of stereoisomers (delta form, lambda form), and any one of these stereoisomers and mixtures thereof are included.

[0018] The ruthenium complexes of the present invention may contain isotopes (e.g. 2 H, 3 H, 13 C. 14C. 15 N, 18 F, 32 This includes compounds labeled with 1,2-dihydropyridine (P, etc.) and deuterium converters.

[0019] The method for producing the ruthenium complex of the present invention is not particularly limited, and the complex can be produced by a known method, for example, according to the method described in Japanese Patent No. 3750011.

[0020] The ruthenium complex of the present invention can be used for the treatment of cancer, including the inhibition of tumor growth, tumor shrinkage, maintenance of tumor size, inhibition of cancer recurrence, inhibition of metastasis, alleviation and remission of symptoms, slowing down the rate of progression of symptoms, and enhancing the effectiveness of other cancer treatments.

[0021] Breast cancer is cancer that occurs in the mammary gland, and currently treatment strategies are determined according to subtype. Subtypes are classified according to whether hormone receptors, including estrogen receptors and progesterone receptors, are positive or negative, and whether HER2 (human epidermal growth factor receptor type 2), a protein involved in cell proliferation, is positive or negative. For example, breast cancer is classified into hormone receptor positive / HER2 positive breast cancer, hormone receptor positive / HER2 negative breast cancer, hormone receptor negative / HER2 positive breast cancer, and triple negative breast cancer (ER (estrogen receptor), PgR (progesterone receptor), and HER2 are all negative).

[0022] Lung cancer is divided into small cell lung cancer and non-small cell lung cancer, and non-small cell lung cancer includes histological types such as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. In non-small cell lung cancer, mutations in the EGFR gene, ALK gene, ROS1 gene, etc. are tested for in cancer cells contained in tissues and pleural effusions collected by biopsy, and if gene mutations are positive, treatment is often given according to the mutated gene. For lung cancer with EGFR (epidermal growth factor receptor) gene mutations, tyrosine kinase inhibitors such as gefitinib and erlotinib are the standard treatment, but the problem is that they acquire drug resistance within one to two years and become ineffective.

[0023] The ruthenium complex represented by formula (I) or its pharma- ceutically acceptable salt can be used to treat various cancers. It can be preferably used to treat breast cancer, lung cancer, colon cancer, cervical cancer, neuroblastoma, and leukemia. It can be more preferably used to treat breast cancer, lung cancer, and neuroblastoma.

[0024] The ruthenium complex represented by formula (I) or a pharma- ceutically acceptable salt thereof can be more suitably used for hormone receptor-negative breast cancer, and more suitably used for hormone receptor-negative, HER2-positive breast cancer and triple-negative breast cancer.

[0025] The ruthenium complex represented by formula (I) or a pharma- ceutically acceptable salt thereof can be suitably used for EGFR (epidermal growth factor receptor) gene mutation-positive lung cancer.

[0026] The ruthenium complex represented by formula (II) or a pharma- ceutically acceptable salt thereof can be used for the treatment of at least one cancer selected from the group consisting of breast cancer, lung cancer, and leukemia, and is more preferably used for breast cancer and lung cancer.

[0027] The ruthenium complex represented by formula (II) or a pharma- ceutically acceptable salt thereof can be preferably used for hormone receptor-negative breast cancer, and more preferably for triple-negative breast cancer and hormone receptor-negative, HER2-positive breast cancer.

[0028] The ruthenium complex represented by formula (II) or a pharma- ceutically acceptable salt thereof can be suitably used for EGFR (epidermal growth factor receptor) gene mutation-positive lung cancer.

[0029] The compositions of the present invention can be used in photodynamic therapy (PDT).

[0030] The treatment with the composition of the present invention can be a single treatment, but can also be performed in parallel with other cancer treatments. There is no limitation on other cancer treatments as long as they are used in cancer treatment. For example, surgical therapy (e.g., resection or excision), chemotherapy, and radiation therapy can be included. By combining the treatment with the composition of the present invention with other cancer treatments, the effect of the cancer treatment can be enhanced.

[0031] The composition of the present invention may contain other anticancer agents as active ingredients.

[0032] The composition of the present invention can contain the ruthenium complex of the present invention and a pharma- ceutically acceptable carrier. Such carriers include excipients (e.g., sugar derivatives such as mannitol and sorbitol; starch derivatives such as corn starch and potato starch; or cellulose derivatives such as crystalline cellulose), lubricants (e.g., stearic acid metal salts such as magnesium stearate; or talc), binders (e.g., hydroxypropylcellulose, hydroxypropylmethylcellulose, or polyvinylpyrrolidone), disintegrants (e.g., cellulose derivatives such as carboxymethylcellulose and carboxymethylcellulose calcium), water, preservatives (e.g., paraoxybenzoic acid esters such as methylparaben and propylparaben; or alcohols such as chlorobutanol and benzyl alcohol), pH adjusters (e.g., inorganic acids such as hydrochloric acid, sulfuric acid, or phosphoric acid, organic acids such as acetic acid, succinic acid, fumaric acid, or malic acid, or salts thereof), and diluents (e.g., water for injection), which may be formulated alone or in combination of two or more of commonly used pharmaceutical preparation carriers. The composition of the present invention includes a liquid preparation in which the active ingredient is dissolved in water.

[0033] The ruthenium complex of the present invention can be mixed with the above-mentioned carrier as necessary and then formulated into a dosage form such as a tablet, granule, capsule, powder, suppository, liquid, suspension, or emulsion. The ruthenium complex of the present invention can be administered orally, intravenously, intraarterially, transdermally, or via the mucosa.

[0034] The ruthenium complex of the present invention is formulated into the above-mentioned dosage form and then administered to a subject in need thereof.

[0035] The subject to which the composition of the present invention is administered may be any mammal, including, for example, rodents such as mice, rats, hamsters, guinea pigs, etc., lagomorphs such as rabbits, ungulates such as pigs, cows, goats, horses, sheep, etc., carnivores such as dogs, cats, etc., and primates such as humans, monkeys, rhesus monkeys, cynomolgus monkeys, marmosets, orangutans, chimpanzees, etc. The mammal is preferably a primate, more preferably a human.

[0036] The dosage and frequency of administration of the ruthenium complex in the present invention may vary as appropriate depending on the severity of symptoms, the age, weight, sex, dosage form, administration route, and other conditions of the subject. When administered to humans, the dosage per administration may be, for example, 0.001-100 mg, 0.01-10 mg, or 0.1-1 mg of the active ingredient. The frequency of administration may be once or multiple times per day, or once every few days or weeks.

[0037] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to these examples. EXAMPLES

[0038] <Example 1> Synthesis of [Ru(47dpphen)2(5dmbpy)](PF6)2

[0039] 1. Synthesis of [Ru(47dpphen)2Cl2]

[0040] In a 200mL recovery flask, 196.0mg of RuCl3·nH2O, 501.3mg of 4,7-diphenyl-1,10-phenanthroline (47dpphen), 224.5mg of LiCl, and 15mL of DMF as a solvent were added, and the mixture was refluxed under Ar atmosphere at 140℃ for 24 hours. After refluxing, the mixture was allowed to cool to room temperature, 150mL of acetone was added, and the mixture was left to stand in a refrigerator overnight to precipitate. The resulting solid was filtered under suction and washed alternately with distilled water and diethyl ether. The yield was 374.8mg, and the yield was 47.4%.

[0041] [ka]

[0042] 1 The compound was identified as [Ru(47dpphen)2Cl2] by H-NMR spectroscopy. 1 The H-NMR spectrum (400 MHz, DMSO-d, 298 K) is shown in FIG. 1, and the analysis results are shown below.

[0043] δ10.45(d,1H,J=8.0Hz),8.25(m,2H),8.07(t,2H,J=12Hz),7.86(d,2H,J=8.0Hz),7.7 4(t,2H,J=12Hz),7.67(d,1H,J=8.0Hz),7.56(d,5H,J=4.0Hz),7.41(d,1H,J=8.0Hz).

[0044] 2. Synthesis of [Ru(47dpphen)2(5dmbpy)](PF6)2

[0045] 5 mL of ethylene glycol was added to 49.1 mg of [Ru(47dpphen)2Cl2] and 12.2 mg of 5,5'-dimethyl-2,2'-bipyridine (5dmbpy), and after Ar degassing, synthesis was performed by irradiating microwaves at 250°C for 3 minutes. After cooling to room temperature, an aqueous solution containing 193.7 mg of NaPF6 was added and left to stand overnight. The precipitated solid was filtered, washed with water / ether, and then vacuum dried. Then, recrystallization was performed with acetone / ether. The yield was 40.3 mg, and the yield was 55.3%.

[0046] [ka]

[0047] 1 The compound was identified as [Ru(47dpphen)2(5dmbpy)](PF6)2 by H-NMR and ESI-MS spectra. 1 The H-NMR spectrum (400 MHz, DMSO-d6, 298 K) is shown in FIG. 2, and the analysis results are shown below.

[0048] δ8.79(d,1H,J=8.0Hz),8.30(d,1H,J=8.0Hz),8.26(d,3H,J=8.0Hz),8.15(d,1H,J=8.0Hz),7.96(d,1H,J=8.0Hz),7.71(m,12H),2.51(s,3H).

[0049] As a result of ESI-MS spectrum (solvent: CH3CN), the chemical formula C 60 H 44 [M] is the divalent cation of N6Ru 2+ The target substance was confirmed by observing a mass peak of 475.1338, which matches the isotope distribution of ruthenium (Figure 3).

[0050] <Example 2> Synthesis of [Ru(47dpphen)2(4dmbpy)](PF6)2

[0051] 5 mL of ethylene glycol was added to 49.8 mg of [Ru(47dpphen)2Cl2] obtained as an intermediate in Example 1 and 11.5 mg of 4,4'-dimethyl-2,2'-bipyridine (4dmbpy), and after Ar degassing, synthesis was performed by irradiating microwaves at 250°C for 3 minutes. After cooling to room temperature, an aqueous solution containing 174.2 mg of NaPF6 was added and left to stand overnight. The precipitated solid was filtered, washed with water / ether, and then vacuum dried. Then, recrystallization was performed three times with acetone / ether. The yield was 30.9 mg, and the yield was 41.9%.

[0052] [ka]

[0053] 1 The compound was identified as [Ru(47dpphen)2(4dmbpy)](PF6)2 by H-NMR and ESI-MS spectra. 1 The H-NMR spectrum (400 MHz, DMSO-d, 298 K) is shown in FIG. 4, and the analysis results are shown below.

[0054] δ8.81(s,1H),8.34(d,1H,J=8.0Hz),8.26(d,2H,J=8.0Hz),8.22(d,1H,J=4.0Hz), 7.95(dd,1H,J=4.0Hz),7.68(m,12H),7.35(d,1H,J=4.0Hz),2.51(dd,3H,J=8.0Hz)

[0055] As a result of ESI-MS spectrum (solvent: CH3CN), the chemical formula C 60 H 44 [M] is the divalent cation of N6Ru 2+ The target substance was confirmed by observing a mass peak of 475.1338, which matches the isotope distribution of ruthenium (Figure 5).

[0056] <Comparative Example> Synthesis of [Ru(47dpphen)2(bpy)](PF6)2

[0057] 5 mL of ethylene glycol was added to 49.3 mg of [Ru(47dpphen)2Cl2] obtained as an intermediate in Example 1 and 10.1 mg of 2,2'-bipyridine (bpy), and after Ar degassing, synthesis was performed by irradiating microwaves at 250°C for 2 minutes. After cooling to room temperature, an aqueous solution containing 187.9 mg of NaPF6 was added and left to stand overnight. The precipitated solid was filtered, washed with water / ether, and then vacuum dried. Then, recrystallization was performed three times with acetone / ether. The yield was 28.6 mg, and the yield was 40.0%.

[0058] [ka]

[0059] As a result of ESI-MS spectrum (solvent: CH3CN), the chemical formula C 58 H 40 [M] is the divalent cation of N6Ru 2+ The target substance was confirmed by observing a mass peak of 461.1181, which matches the isotope distribution of ruthenium (Figure 6).

[0060] <Test Example> Evaluation of anticancer activity of the ruthenium complexes obtained in the examples

[0061] The drugs used in the test are listed below. HRM-19: [Ru(47dpphen)2(5dmbpy)](PF6): synthesized in Example 1 HRM-18: [Ru(47dpphen)2(4dmbpy)](PF6): synthesized in Example 2 HRM-17: [Ru(47dpphen)2(bpy)](PF6)2: Synthesized in Comparative Example Carboplatin (CBDCA): Obtained from TCI

[0062] The human cancer cell lines used in the test are as follows: PC-9 was obtained from the Cell Bank of the Institute of Development, Aging and Cancer, Tohoku University, and the other cells were obtained from ATCC. A549: Lung cancer cell line PC-9: Lung cancer cell line (EGFR gene mutation-positive lung cancer cell line) MDA-MB-231: Breast cancer cell line (triple negative breast cancer cell line) SKBR-3: Breast cancer cell line (hormone receptor negative, HER2 positive breast cancer cell line) HCT116: colon cancer cell line Hela: a cervical cancer cell line SHSY5Y: Neuroblastoma cell line Jurkat: Blood cancer cell line (derived from human T-cell leukemia)

[0063] <Test Example 1> Cell viability of human cancer cell lines

[0064] Lung cancer cell lines (A549 and PC-9), breast cancer cell lines (MDA-MB-231 and SKBR-3), colon cancer cell line (HCT116), cervical cancer cell line (Hela), and neuroblastoma cell line (SHSY5Y) were cultured in DMEM medium (10% fetal bovine serum, 0.1% penicillin-streptomycin) (Nacalai Tesuque) in a 10 cm petri dish until the cell density reached 80% in an incubator at 37°C and 5% CO2. The cultured cells were detached with 0.25% trypsin-EDTA (Nacalai Tesuque) solution, suspended in DMEM medium, and centrifuged at 1000 rpm for 5 minutes. The medium was removed from the centrifuged cells, suspended again in DMEM medium, and the cell count was confirmed using a hemocytometer. Then, 1 × 10 cells were placed in a 96-well plate. 4The cells were seeded at 100 cells / well. The 96-well plate was cultured at 37°C under 5% CO2 for 24 hours, after which each drug was added (final concentration 100μM). After drug addition, the plate was cultured at 37°C in a dark incubator under 5% CO2 for 72 hours. The DMEM medium containing the drug was then removed, followed by addition of DMEM medium (10% Fetal Bovine Serum, 0.1% Penicillin-Streptomycin) containing Cell Count Reagent SF (Nacalai Tesque) and culture for 3 hours, after which the number of viable cells was measured using a microplate reader model 680 (measurement wavelength 450nm) (BIORAD).

[0065] Blood cancer cell line (Jurkat) was cultured in RPMI1640 medium (10% Fetal Bovine Serum, 0.1% Penicillin-Streptomycin) (Nacalai Tesque) in a 10 cm petri dish in an incubator at 37°C and 5% CO2 until the density reached 80%. The cell suspension was centrifuged at 2000 rpm for 10 minutes, the supernatant was removed, the cell number was confirmed with a hemocytometer, and 1 × 10 cells were placed in a 96-well plate. 4 Cells were seeded at 100 cells / well. The 96-well plate was cultured at 37°C under 5% CO2 for 24 hours, after which each drug was added (final concentration 100μM). After culturing at 37°C for 72 hours in a dark incubator under 5% CO2, Cell Count Reagent SF (Nacalai Tesque) was added to each well at 10% of the medium volume, and the reaction was allowed to proceed for 3 hours. After the reaction, the number of live cells was measured using a microplate reader model 680 (measurement wavelength 450nm) (BIORAD).

[0066] The cell viability was calculated from the average number of viable cells in each well. The cell viability was expressed as the ratio (%) of the number of viable cells in each drug-treated well to the number of viable cells in the negative control (cells not treated with drug). The results are shown in Figure 7.

[0067] <Test Example 2> 50% inhibitory concentration (IC50) of breast cancer cell line MDA-MB-231

[0068] The IC50 of each drug against the breast cancer cell line MDA-MB-231 was determined. The test method involved measuring drug concentrations (final concentrations) at five points: 100μM, 10μM, 1μM, 0.1μM, and 0.01μM, and calculating the concentration at which cell proliferation rate reached 50%. The results are shown in Table 1. It was revealed that HRM-19 and HRM-18 have excellent anticancer activity against triple-negative breast cancer.

[0069] [Table 1]

[0070] <Test Example 3> Cell cycle analysis of breast cancer cell line MDA-MB-231 MDA-MB-231 was cultured in a 10 cm petri dish in DMEM medium (10% fetal bovine serum, 0.1% penicillin-streptomycin) (Nacalai Tesuque) at 37°C in an incubator under 5% CO2 until the cell density reached 80%. The cultured cells were detached with a 0.25% trypsin-EDTA (Nacalai Tesuque) solution, suspended in DMEM medium, and centrifuged at 1000 rpm for 5 minutes. The medium was removed from the centrifuged cells, and the cells were suspended again in DMEM medium. The cell count was confirmed using a hemocytometer, and 1 × 10 cells were placed in a 6 cm petri dish. 6The cells were seeded at 1000 cells / dish. After 24 hours of culturing in a 6 cm dish, each drug (final concentration 10 μM) was added. 24 hours after drug addition, the supernatant was collected in a 15 ml centrifuge tube, and the adherent cells were detached with a 0.25% trypsin-EDTA (Nacalai Tesuque) solution and collected in the centrifuge tube that had collected the supernatant. The collected cells were treated according to the procedure of the BD Cycletest™ Plus DNA Reagent Kit (BD Biosciences). The treated cells were measured within 1 hour using an LSRFortessa™ X-20 flow cytometer (BD Biosciences), and the cell cycle was analyzed using BD FACSDiva™ software (BD Biosciences). The results are shown in Figure 8.

[0071] HRM-19 and HRM-18 increased the number of cells in the G0 / G1 phase of the cell cycle and decreased the number of cells in the S and G2 / M phases. HRM-19 and HRM-18 also suppressed the percentage of cells in the S phase compared to carboplatin. It was revealed that HRM-19 and HRM-18 arrest the cell cycle of triple-negative breast cancer cells at the G0 / G1 phase and suppress cell proliferation.

[0072] From the above results, it is clear that the ruthenium complex or a pharma- ceutical acceptable salt thereof of the present invention exhibits a high therapeutic effect against cancer. [Industrial Applicability]

[0073] This invention will make a great contribution to future cancer treatment.

Claims

1. Formula (I): 【Chemistry 1】 or a pharmacy acceptable salt thereof.

2. A composition for cancer treatment comprising the ruthenium complex according to claim 1 or a pharma- ceutically acceptable salt thereof.

3. The composition according to claim 2, wherein the cancer is at least one selected from the group consisting of breast cancer, lung cancer, colon cancer, cervical cancer, neuroblastoma, and leukemia.

4. The composition of claim 3 , wherein the cancer is breast cancer.

5. The composition of claim 4, wherein the breast cancer is hormone receptor negative breast cancer.

6. The composition of claim 5, wherein the hormone receptor negative breast cancer is triple negative breast cancer.

7. The composition of claim 5, wherein the hormone receptor negative breast cancer is HER2 positive breast cancer.

8. The composition of claim 3 , wherein the cancer is lung cancer.

9. The composition according to claim 8, wherein the lung cancer is an EGFR gene mutation-positive lung cancer.

10. The composition of claim 3 , wherein the cancer is neuroblastoma.

11. Formula (II): 【Chemistry 2】 or a pharma- ceutically acceptable salt thereof, wherein the cancer is at least one selected from the group consisting of breast cancer, lung cancer, and leukemia.

12. The composition of claim 11 , wherein the cancer is breast cancer.

13. The composition of claim 12, wherein the breast cancer is a hormone receptor negative breast cancer.

14. The composition of claim 13, wherein the hormone receptor negative breast cancer is triple negative breast cancer.

15. The composition of claim 13, wherein the hormone receptor negative breast cancer is HER2 positive breast cancer.

16. The composition of claim 11 , wherein the cancer is lung cancer.

17. The composition of claim 16, wherein the lung cancer is an EGFR gene mutation-positive lung cancer.